April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
Activation of Plasmin Proteolytic System in Glaucoma and the Neuroprotective Role of TrkB Receptor Agonists
Author Affiliations & Notes
  • Vivek Kumar Gupta
    Australian School of Advanced Medicine, Macquarie University, North Ryde, Sydney, NSW, Australia
  • Yuyi You
    Australian School of Advanced Medicine, Macquarie University, North Ryde, Sydney, NSW, Australia
  • Veer Gupta
    School of Medical Sciences, Edith Cowan University, Perth, WA, Australia
  • Mojtaba Golzan
    Australian School of Advanced Medicine, Macquarie University, North Ryde, Sydney, NSW, Australia
  • Nadia Al-Adawy
    Australian School of Advanced Medicine, Macquarie University, North Ryde, Sydney, NSW, Australia
  • Stuart L Graham
    Australian School of Advanced Medicine, Macquarie University, North Ryde, Sydney, NSW, Australia
    Save Sight Institute, Sydney University, Sydney, NSW, Australia
  • Footnotes
    Commercial Relationships Vivek Kumar Gupta, None; Yuyi You, None; Veer Gupta, None; Mojtaba Golzan, None; Nadia Al-Adawy, None; Stuart Graham, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 2435. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Vivek Kumar Gupta, Yuyi You, Veer Gupta, Mojtaba Golzan, Nadia Al-Adawy, Stuart L Graham; Activation of Plasmin Proteolytic System in Glaucoma and the Neuroprotective Role of TrkB Receptor Agonists. Invest. Ophthalmol. Vis. Sci. 2014;55(13):2435.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Involvement of proteases has been implicated in remodelling of the extracellular matrix (ECM) in the optic nerve head (ONH) leading to its excavation and an increase in cup to disc ratio in glaucoma. Plasmin proteolytic activity in particular has been implicated in imparting damage to the retina and retinal ganglion cells (RGCs). We have shown previously that Tropomyosin related kinase B (TrkB) receptor activation is neuroprotective for the RGCs in glaucoma. Here, we compared the activity and expression profile of plasmin in normal and glaucomatous conditions and evaluated the effects of TrkB receptor agonist- 7,8 dihydroxyflavone (7,8DHF) treatment on the ECM degradation in glaucoma.

Methods: Ocular hypertension was induced unilaterally in adult Sprague-Dawley rats by repetitive injection of microspheres (weekly) into the anterior chamber of the eye (n=16). Intraocular pressure was monitored using a rebounded tonometer (iCare). One set of rats was treated with a TrkB receptor agonist-7,8 DHF (5mg/kg, i.p, weekly) (n=8). After 20 weeks, rats were sacrificed, perfused with saline, and the ONH region of the retina was collected. Plasmin activity was measured using specific ELISA kits and the expression levels determined by immunohistochemistry and western blotting.

Results: Our results indicate that the plasmin activity was significantly higher in the ONH of rat eyes exposed to experimental glaucoma compared to the contralateral controls (p<0.001). Plasmin expression was primarily observed to be localised around the ONH region in retinal flat mounts and was not altered to any considerable extent in the high IOP exposed retinas. Treatment with 7,8 DHF lead to a significant decline in the plasmin proteolytic activity (p<0.001) and a reduction in the collagen degradation products in the ONH in glaucomatous eyes.

Conclusions: This study demonstrates for the first time activation of plasmin proteolytic activity as a pathological change in glaucoma in vivo. Further investigations may provide insights into the failure of a molecular regulatory mechanism which would normally regulate the plasmin activity in the retina. Administration of 7,8DHF significantly reduced both the plasmin activation as well as degradation of ECM proteins in the ONH.

Keywords: 531 ganglion cells • 615 neuroprotection • 543 growth factors/growth factor receptors  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×